Breaking News

Canon Medical Offers New Liver Reporting Tool for Ultrasound

To help easily and accurately determine cut off values, Canon Medical Systems USA, Inc.’s premium AplioTM i-series ultrasound platform is now available with software to display the calculated measurement averages from multiple samples of the liver, customizable based on the “Rule of Four.”

Rithem Life Sciences Joins Innovators’ Network at American Heart Association Center for Health Technology & Innovation

The Center is focused on building and fostering health technology relationships to develop innovative and scalable solutions.

1st Patients Enrolled in STEM Trial for `Treatment of Chronic Subdural Hematoma

This marks the first patients enrolled in a prospective, randomized, international trial of a liquid embolic agent for the treatment of chronic subdural hematoma (cSDH), a common disease affecting primarily older adults.

Genius AI Detection Receives FDA Clearance – New Deep Learning-based Software Designed to Help Radiologists Detect Subtle Potential Cancers in Breast Tomosynthesis Images

This new technology, represents a pivotal milestone in the early detection of breast cancer, as studies showed Genius AI Detection software aids in the identification and early detection of breast cancer when used with the Genius® 3D Mammography™ exam.

Passio Pump Drainage System Granted 510(k) for Additional Indication for Home Use

The Passio Pump Drainage System consists of the Passio Catheter, a Handheld Control Unit (pump) and a Disposable Collection Kit, which includes a redressing kit, for drainage of recurrent and symptomatic pleural effusion.

Clarity Pharmaceuticals Announced the US FDA Grants Rare Pediatric Disease Designation to 64Cu-SARTATE™

September 9, 2020

Clarity Pharmaceuticals is a clinical-stage radiopharmaceutical company focused on the treatment of serious disease. Today they announced the U.S. Food and Drug Administration (FDA) has granted Rare Paediatric Disease Designation (RPDD) to 64Cu-SARTATE™, a diagnostic for the clinical management of neuroblastoma.

Clarity Pharmaceuticals Executive Chairman Dr. Alan Taylor commented, “We are very excited to have received the RPDD status for the diagnostic application of SARTATE™ in children with neuroblastoma. This comes shortly after Clarity has been granted RPDD for the treatment of neuroblastoma with 67Cu-SARTATE™ for the therapeutic application, announced on the 3rd of June 2020.”

The FDA defines a “rare pediatric disease” (RPD) as a serious or life-threatening disease primarily affecting individuals aged 18 years or younger that impacts fewer than 200,000 people in the United States. The program is intended to facilitate the development of new drugs and biologics for the prevention and treatment of RPDs.

Neuroblastoma most often occurs in children younger than 5 years of age and presents when the tumor grows and causes symptoms. It is the most common type of cancer to be diagnosed in the first year of life and accounts for around 15% of pediatric cancer mortality.[1] High-risk neuroblastoma accounts for approximately 45% of all neuroblastoma cases. Patients with high-risk neuroblastoma have the lowest 5-year survival rates at 40%-50%.[2]

Upon FDA marketing approval of 64Cu-SARTATE™ for neuroblastoma with RPD designation, Clarity would be eligible to receive a tradable Priority Review Voucher (PRV). The PRV shortens the FDA review period of a New Drug Application (NDA) for another product to an expedited period of six months, which is a huge benefit for drug developers. The voucher, if awarded, may be sold or transferred to another company. To date, PRVs have been sold for between US$67.5 million and US$350 million, with the most recent PRV being purchased by Merck from Lumos Pharma for a value of US$100 million in July 2020.[3]

“With 67Cu-SARTATE™, a therapeutic for the clinical management of neuroblastoma, also having been awarded RPDD status[4], Clarity may be eligible for two Priority Review Vouchers if both treatments get FDA approval,” commented Dr. Taylor.

“We have seen incredibly strong support from our collaborators and advisors in the development of SARTATE™ for neuroblastoma and are looking forward to the results from our US-based trial at the Memorial Sloan Kettering Cancer Centre[5]. It is evident that there is a large unmet need in the management and treatment of this devastating disease and we are aiming to improve outcomes for this important patient population with both the diagnostic and therapeutic applications of SARTATE™” said Dr. Taylor.


References

  1. Nadja C. Colon and Dai H. Chung 2011, “Neuroblastoma”, Advances in Paediatrics, <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3668791/>
  2. Valeria Smith and Jennifer Foster 2018, High Risk Neuroblastoma Treatment Review, <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6162495/>
  3. Lumos Pharma Announces Sale of Priority Review Voucher 27 July 2020, <https://www.globenewswire.com/news-release/2020/07/27/2068182/0/en/Lumos-Pharma-Announces-Sale-of-Priority-Review-Voucher.html>
  4. Clarity Pharmaceuticals Announces that the US FDA Grants Rare Paediatric Disease Designation to 67Cu-SARTATE™ for the Treatment of Neuroblastoma 3 June 2020, <https://www.claritypharmaceuticals.com/news/rpdd/>
  5. ClinicalTrials.gov Identifier: NCT04023331 <https://clinicaltrials.gov/ct2/show/NCT04023331>

Latest Posts

Face Shield Market Is Estimated to Grow Globally from USD 3.0 billion in 2020 to USD 4.1 Bil by 2025, at a CAGR of 65%

Face shield market size is estimated to grow globally from USD 3.0 billion in 2020 to USD 4.1 billion by 2025, at a CAGR of 6.5%.

Acquisition of Moldworx, LLC by Sunningdale Tech Ltd Completed Effective November 6, 2020

On November 6, 2020, the acquisition of Moldworx by global precision plastics manufacturer, Sunningdale Tech Ltd (Singapore) via its wholly-owned subsidiary, Sunningdale Tech Inc, a Michigan Corporation, was completed.

1st PSMA-Targeted PET Imaging Drug for Men with Prostate Cancer Receives FDA Approval

"Ga 68 PSMA-11 is an important tool that can aid health care providers in assessing prostate cancer," said Alex Gorovets, M.D., acting deputy director of the Office of Specialty Medicine in FDA's Center for Drug Evaluation and Research. "With this first approval of a PSMA-targeted PET imaging drug for men with prostate cancer, providers now have a new imaging approach to detect whether or not the cancer has spread to other parts of the body."

Don't Miss

New England Biolabs Announces Further Expansion of Their RNA Depletion Product Portfolio with the Launch of the NEBNext Custom RNA Depletion Design Tool and NEBNext RNA Depletion Core Reagent...

Together, these enable a fully customizable workflow for improved removal of specific RNAs, including abundant RNAs such as ribosomal RNA

INTERCEPT Blood System for Cryoprecipitation Receives FDA Approval States Cerus Corporation

The system is used to produce Pathogen Reduced Cryoprecipitated Fibrinogen Complex for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. 

Genetron Health Provides Update on HCCscreen™ for Liver Cancer Early Screening in China

Establishes joint venture with Wuxi municipal government; Expects the commercialization and revenues of HCCscreen to accelerate in China.

Research Paper Showing ProtoKinetix AAGP® Enhanced Stem Cell Derived Retina Precursor Cells Restoration of Vision

ProtoKinetix notes the research paper has been submitted to a prestigious journal specializing in tissue regeneration for peer review and editing.

OrganaBio to Expand Its cGMP Cell and Gene Therapy Manufacturing Facility: 19,000 Sq. Ft. Slated to Commence Operations In Q3 2021

OrganBio, a Miami-based cGMP facility, will include process development space, ISO 7 cleanrooms, state-of-the-art scientific equipment, analytics and QC laboratories, and a suite of support services to enable OrganaBio and its partners to rapidly and economically self-manufacture clinical materials.